The use of covered stents in aortoiliac obstructions: a systematic review and meta-analysis

Joost A Bekken1, Hidde Jongsma2, Bram Fioole2

  • 1Department of Vascular Surgery, Maasstad Ziekenhuis, Rotterdam, The Netherlands - joostbekken@hotmail.com.

Insights

Covered stents show potential for improving patency in complex aortoiliac occlusive disease (TASC C and D lesions). However, limited high-quality evidence necessitates further research to optimize their use in specific patient subsets.

Area of Science:

  • Vascular Surgery
  • Endovascular Interventions
  • Medical Device Technology

Background:

  • Endovascular treatment is preferred for aortoiliac occlusive disease, but patency lags behind open surgery.
  • Covered stents are explored to enhance endovascular treatment outcomes.
  • This review evaluates literature on covered stents for aortoiliac occlusive disease.

Purpose of the Study:

  • To systematically review and meta-analyze the efficacy of covered stents in treating aortoiliac occlusive disease.
  • To compare the patency rates of covered stents versus bare-metal stents.
  • To assess the impact of covered stents on complex lesions (TASC C and D).

Main Methods:

  • Comprehensive literature search of MEDLINE, Embase, and Cochrane databases.
  • Inclusion of all studies on covered stents and stent grafts for endovascular aneurysm repair.
  • Systematic review and meta-analysis of identified studies.

Main Results:

  • Nineteen studies (12 single-arm, 6 retrospective, 1 RCT) were analyzed.
  • No significant difference in primary patency between covered and bare-metal stents at 1, 2, and 3-5 years.
  • Covered stents showed a significant benefit in TASC C and D lesions.

Conclusions:

  • Limited high-quality evidence supports covered stents for aortoiliac occlusive arterial disease.
  • Covered stents may improve patency in TASC C and D lesions.
  • Further research is needed to identify specific lesion characteristics benefiting from covered stent placement due to TASC heterogeneity.
Abstract

Related Concept Videos

Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
361
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
398
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
476
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
545